Heatwurx (PCSA) Projected to Release Quarterly Earnings on Thursday

Heatwurx (NASDAQ:PCSA) is expected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Heatwurx Price Performance

NASDAQ PCSA traded up $0.08 on Tuesday, hitting $2.21. 33,594 shares of the stock were exchanged, compared to its average volume of 141,305. The company’s 50-day moving average price is $2.26 and its two-hundred day moving average price is $2.56. Heatwurx has a 52-week low of $1.67 and a 52-week high of $14.24. The company has a market capitalization of $6.12 million, a price-to-earnings ratio of -0.24 and a beta of 0.98.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Heatwurx currently has an average rating of “Hold” and an average target price of $25.00.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.